The drugs developer cut sales guidance several times last year

Issue Contents

Editor's View
Feature
Funds
Great Ideas
Investment Trusts
News
Personal Finance
Week Ahead

Issue Contents

Editor's View
Feature
Funds
Great Ideas
Investment Trusts
News
Personal Finance
Week Ahead